Intracoronary administration of nicorandil-induced cardiac arrest during primary percutaneous coronary intervention

A case report

Shu-Jian Wei, MD\textsuperscript{a,b,c,d,e}, Fang-Yun Luan, BS\textsuperscript{c}, Da-yu He, BS\textsuperscript{a,b,c,d,e}, Feng Xu, MD\textsuperscript{a,b,c,d,e}, Yu-Guo Chen, MD\textsuperscript{a,b,c,d,e,*}

Abstract

Rationale: Primary percutaneous coronary intervention (PPCI) is the most effective therapy for patients with an acute ST-segment elevation myocardial infarction (STEMI). However, up to half of STEMI patients suffer from coronary microvascular dysfunction, presenting as the slow flow or no-reflow phenomenon.

Patients concerns: A 78-year-old man was admitted to the chest pain center with sudden chest pain and tightness for about an hour.

Diagnoses: Electrocardiography demonstrated ST-segment elevation in leads II, III, aVF, and third-degree atrioventricular block. Coronary angiography showed acute total occlusion in the distal right coronary artery (RCA).

Interventions: PPCI was performed on the patient. After thrombus aspiration, a stent was placed in the distal RCA. As coronary angiography showed TIMI grade 2 flow in RCA, 6mg nicorandil was intracoronary administrated in twice. Immediately, cardiac arrest occurred and cardiopulmonary resuscitation (CPR) was performed.

Outcomes: The patient survived and had a good outcome during follow-up for >6 months.

Lessons: Up to now, there has been no case report of cardiac arrest caused by nicorandil. Although intracoronary nicorandil is one of the most commonly used methods to improve coronary flow, much more attention should be paid to side effects of nicorandil.

Abbreviations: CFR = coronary flow reserve, CPR = cardiopulmonary resuscitation, CTFC = corrected TIMI frame count, IMR = index of microvascular resistance, LAD = left anterior descending artery, LCX = left circumflex artery, MBG = myocardial blush grade, MCE = myocardial contrast echocardiography, PD = posterior descending artery, PL = posterior left ventricular branch, PPCI = primary percutaneous coronary intervention, RCA = right coronary artery, STEMI = ST-segment elevation myocardial infarction, TFG = TIMI flow grades, TMPG = TIMI myocardial perfusion grade.

Keywords: cardiac arrest, microvascular dysfunction, nicorandil, PPCI

1. Introduction

Acute thrombotic occlusion of a coronary artery results in acute ST-segment elevation myocardial infarction (STEMI).\textsuperscript{11} Timely reperfusion therapy with fibrinolytic drugs or primary percutaneous coronary intervention (PPCI) restores blood flow to ischemic myocardium and limits myocardial infarct size.\textsuperscript{2} PPCI has many advantages over thrombolysis, including greater reopening rates of the infarct-related artery and higher coronary flow grades.\textsuperscript{3} Nevertheless, up to 50% of STEMI patients performed with PPCI do not achieve ideal coronary blood flow, which is referred to as the slow flow or no-reflow phenomenon, attributing to microvascular dysfunction or obstruction.

Intracoronary administration of nicorandil reduced the occurrence of slow flow or no-reflow phenomenon by improving microvascular circulation in patients with acute myocardial infarction.\textsuperscript{4,14} The mechanisms of intracoronary nicorandil include dilation of coronary microcirculation, ischemic preconditioning, antiarrhythmia, and reduction of reperfusion injury.\textsuperscript{5} Nicorandil can be used in patients with bradyarrhythmias and/or atrioventricular conduction blocks.\textsuperscript{6-7} In this report, we found intracoronary nicorandil-induced sudden cardiac arrest in a male patient with STEMI (inferior wall).

2. Case report

The study was approved by the Ethics Review Committee of Qilu Hospital, Shandong University (approval no.: 2018101).
The patient has provided informed consent for publication of the case.

A 78-year-old man suffered from sudden chest pain and tightness for about an hour. He had a history of 10-year hypertension and kept taking amlodipine. Physical examination showed the heart rate was 30 bpm and blood pressure was 92/60 mm Hg. A 12-lead electrocardiogram was obtained and demonstrated ST-segment elevation in leads II, III, aVF, and third-degree atrioventricular block (Fig. 1). He was preliminarily diagnosed with acute STEMI (inferior wall) and third-degree atrioventricular block. Immediate coronary angiography showed that no severe stenosis was found in the left anterior descending

Figure 1. The first electrocardiogram performed in chest pain center.
artery (LAD) and left circumflex artery (LCX) and total occlusion was found in the distal right coronary artery (RCA) (Fig. 2A–C). After predilation with a 2.0 × 20 mm balloon and thrombus aspiration, the patient regained sinus heart rate around 80 bpm immediately. As 90% stenosis was found in the ostium of posterior descending artery (PD), a 2.25 × 18 mm stent was implanted in the distal RCA, crossing the ostium of posterior left ventricular branch (PL) (Fig. 2D–F). After postdilatation with a 2.75 × 8 mm NC balloon, angiography showed TIMI grade 2 flow in RCA (Fig. 2G). Then, 6 mg nicorandil was intracoronary administered via guiding catheter in twice within 2 minutes. Unexpectedly, the heart rate dropped to zero. Cardiopulmonary resuscitation (CPR) was performed and 1 mg adrenaline was intravenously injected. Within few minutes, his cardiac pumping was recovered. Repeated angiography showed TIMI grade 3 flow in the RCA finally (Fig. 2H). The patient was stable during follow up for >6 months.

3. Discussion
Microvascular dysfunction termed as slow flow or no-reflow phenomenon occurs in up to half of patients with STEMI even after revascularization of the culprit artery. Microvascular dysfunction limits the restoration of blood supply and the delivery of endogenous promoters responsible for postinfarction remodeling. Thus, patients with microvascular dysfunction exhibit larger myocardial infarct size, more early postinfarct complications, more adverse left ventricle remodeling, and worse prognosis. Multiple methods have been used to assess microvascular dysfunction. Evaluating microvascular dysfunction through angiography is relatively convenient and widespread in practice. Methods of angiographic assessment include TIMI flow grades (TFG), TIMI myocardial perfusion grade (TMPG), myocardial blush grade (MBG), and corrected TIMI frame count (CTFC). Myocardial contrast echocardiography (MCE), index of microvascular resistance (IMR), and coronary flow reserve (CFR) are more accurate and reproducible tools to determine microvascular dysfunction. In the present case, acute total occlusion was found in the distal RCA and thrombus aspiration was performed. After stenting and postdilatation, microvascular dysfunction occurred in this patient indicated by TIMI grade 2 flow in RCA. The pathophysiological mechanisms of microvascular dysfunction are still poorly understood. Ischemia-related injury, reperfusion-related injury, distal embolization from the culprit plaque, and thrombus and individual susceptibility to microcirculatory injury might contribute to the occurrence of microvascular dysfunction. As microvascular dysfunction was found after postdilatation, we speculate that distal embolization induced by emboli from fissured plaques or thrombus is the leading cause for the happening of slow flow phenomenon in this patient.

Treatment of microvascular dysfunction remains further studied. Generally, thrombus aspiration and intracoronary administration of medicines might be effective. Although routine thrombus aspiration is not recommended, it may be considered in cases of large residual thrombus burden after opening the artery with a guide wire or a balloon. Intracoronary adenosine, sodium nitroprusside, verapamil, nicorandil, and GPIIb/IIIa inhibitors were tested in several clinical trials and might improve microvascular function. The patient here was at a low blood pressure and experienced atroventricular block, thus nicorandil was preferred to improve blood flow. Nicorandil, a hybrid with nitrate-like and adenosine triphosphate (ATP)-sensitive potassium (KATP) channel activator, is considered to be the optimal drug to improve coronary flow in acute coronary syndromes because of its nearly no effect on heart rate and blood pressure. In this case, we first reported intracoronary administration of nicorandil induced cardiac arrest. Singer et al.[12] have reported a few cases of life-threatening hyperkalemia and hemodynamic disturbance due to KATP channel activation. Lee et al.[13] have also reported a case...
of life-threatening bradycardia due to nicorandil-induced hyperkalemia. We speculate that activation of KATP channel and subsequent hyperkalemia might be the reason for nicorandil-induced cardiac arrest in this case. Repeated angiography showed improved blood flow finally. Thus, intracoronary nicorandil might be useful in the treatment of microvascular dysfunction.

In conclusion, we report the cardiac arrest case induced by intracoronary nicorandil. Microvascular dysfunction frequently occurs during PPCI. Thrombus aspiration and intracoronary medicines should be considered to prevent microvascular dysfunction. Intracoronary nicorandil might improve TIMI flow grade but should be carefully evaluated due to its side effects including cardiac arrest.

Author contributions
Data curation: Fang-Yun Luan.
Supervision: Yu-Guo Chen.
Writing – original draft: Shujian Wei, Da-yu He.
Writing – review and editing: Shujian Wei, Feng Xu.
Shujian Wei orcid: 0000-0002-0896-6032.

References
[1] Niccoli G, Scalone G, Lerman A, et al. Coronary microvascular obstruction in acute myocardial infarction. Eur Heart J 2016;37:1024–33.
[2] Frohlich GM, Meier P, White SK, et al. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 2013;34:1714–22.
[3] Wong DT, Puri R, Richardson JD, et al. Myocardial ‘no-reflow’—diagnosis, pathophysiology and treatment. Int J Cardiol 2013;167:1798–806.
[4] Lee HC, An SG, Choi JH, et al. Effect of intra-coronary nicorandil administration prior to reperfusion in acute ST segment elevation myocardial infarction. Circ J 2008;72:1425–9.
[5] Ota S, Nishikawa H, Takeuchi M, et al. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Signart Multicenter Angioplasty Revascularization Trial (SMART). Circ J 2006;70:1099–104.
[6] Ueda H, Hayashi T, Tsumura K, et al. Intravenous nicorandil can reduce QT dispersion and prevent bradyarrhythmia during percutaneous transluminal coronary angioplasty of the right coronary artery. J Cardiovasc Pharmacol Ther 2004;9:179–84.
[7] Jang HJ, Koo BK, Lee HS, et al. Safety and efficacy of a novel hyperaemic agent, intracoronary nicorandil, for invasive physiological assessments in the cardiac catheterization laboratory. Eur Heart J 2013;34:2055–62.
[8] Fordyce CB, Genb JI, Stone GW, et al. Novel therapeutics in myocardial infarction: targeting microvascular dysfunction and reperfusion injury. Trends Pharmacol Sci 2015;36:605–16.
[9] de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart J 2017;38:3502–10.
[10] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–77.
[11] Rezkalla SH, Dharmashankar KC, Abdalrahman IB, et al. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol 2010;23:429–36.
[12] Singer M, Coluzzi F, O’Brien A, et al. Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 2005;365:1873–5.
[13] Lee HH, Hsu PC, Lin TH, et al. Nicorandil-induced hyperkalemia in a uremic patient. Case Rep Med 2012;2012:812178.